Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1999 Jun;54(6):550–553. doi: 10.1136/thx.54.6.550

New immunosuppressive drugs and lung transplantation: last or least?

J W K van den Berg 1, D Postma 1, G Koeter 1, W van der Bij 1
PMCID: PMC1745495  PMID: 10335012

Full Text

The Full Text of this article is available as a PDF (63.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akselband Y., Harding M. W., Nelson P. A. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc. 1991 Dec;23(6):2833–2836. [PubMed] [Google Scholar]
  2. Bando K., Paradis I. L., Similo S., Konishi H., Komatsu K., Zullo T. G., Yousem S. A., Close J. M., Zeevi A., Duquesnoy R. J. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg. 1995 Jul;110(1):4–14. doi: 10.1016/S0022-5223(05)80003-0. [DOI] [PubMed] [Google Scholar]
  3. Bonnefoy-Berard N., Revillard J. P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996 May;15(5):435–442. [PubMed] [Google Scholar]
  4. Bullingham R., Monroe S., Nicholls A., Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996 Apr;36(4):315–324. doi: 10.1002/j.1552-4604.1996.tb04207.x. [DOI] [PubMed] [Google Scholar]
  5. Cao W., Mohacsi P., Shorthouse R., Pratt R., Morris R. E. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 1995 Feb 15;59(3):390–395. [PubMed] [Google Scholar]
  6. Epinette W. W., Parker C. M., Jones E. L., Greist M. C. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987 Dec;17(6):962–971. doi: 10.1016/s0190-9622(87)70285-0. [DOI] [PubMed] [Google Scholar]
  7. Fahrni J. A., Berry G. J., Morris R. E., Rosen G. D. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation. 1997 Feb 27;63(4):533–537. doi: 10.1097/00007890-199702270-00008. [DOI] [PubMed] [Google Scholar]
  8. Girgis R. E., Tu I., Berry G. J., Reichenspurner H., Valentine V. G., Conte J. V., Ting A., Johnstone I., Miller J., Robbins R. C. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996 Dec;15(12):1200–1208. [PubMed] [Google Scholar]
  9. Goto T., Kino T., Hatanaka H., Nishiyama M., Okuhara M., Kohsaka M., Aoki H., Imanaka H. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc. 1987 Oct;19(5 Suppl 6):4–8. [PubMed] [Google Scholar]
  10. Gregory C. R., Huang X., Pratt R. E., Dzau V. J., Shorthouse R., Billingham M. E., Morris R. E. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995 Mar 15;59(5):655–661. doi: 10.1097/00007890-199503150-00002. [DOI] [PubMed] [Google Scholar]
  11. Griffith B. P., Bando K., Hardesty R. L., Armitage J. M., Keenan R. J., Pham S. M., Paradis I. L., Yousem S. A., Komatsu K., Konishi H. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation. 1994 Mar 27;57(6):848–851. doi: 10.1097/00007890-199403270-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Guilinger R. A., Paradis I. L., Dauber J. H., Yousem S. A., Williams P. A., Keenan R. J., Griffith B. P. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2037–2043. doi: 10.1164/ajrccm.152.6.8520773. [DOI] [PubMed] [Google Scholar]
  13. Horning N. R., Lynch J. P., Sundaresan S. R., Patterson G. A., Trulock E. P. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant. 1998 Aug;17(8):761–767. [PubMed] [Google Scholar]
  14. Iacono A. T., Keenan R. J., Duncan S. R., Smaldone G. C., Dauber J. H., Paradis I. L., Ohori N. P., Grgurich W. F., Burckart G. J., Zeevi A. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1451–1455. doi: 10.1164/ajrccm.153.4.8616581. [DOI] [PubMed] [Google Scholar]
  15. Iacono A. T., Smaldone G. C., Keenan R. J., Diot P., Dauber J. H., Zeevi A., Burckart G. J., Griffith B. P. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med. 1997 May;155(5):1690–1698. doi: 10.1164/ajrccm.155.5.9154878. [DOI] [PubMed] [Google Scholar]
  16. Keenan R. J., Iacono A., Dauber J. H., Zeevi A., Yousem S. A., Ohori N. P., Burckart G. J., Kawai A., Smaldone G. C., Griffith B. P. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg. 1997 Feb;113(2):335–341. doi: 10.1016/S0022-5223(97)70331-3. [DOI] [PubMed] [Google Scholar]
  17. Keenan R. J., Konishi H., Kawai A., Paradis I. L., Nunley D. R., Iacono A. T., Hardesty R. L., Weyant R. J., Griffith B. P. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995 Sep;60(3):580–585. doi: 10.1016/0003-4975(95)00407-C. [DOI] [PubMed] [Google Scholar]
  18. Kelly K., Hertz M. I. Obliterative bronchiolitis. Clin Chest Med. 1997 Jun;18(2):319–338. doi: 10.1016/s0272-5231(05)70382-8. [DOI] [PubMed] [Google Scholar]
  19. Kelly P. A., Gruber S. A., Behbod F., Kahan B. D. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy. 1997 Nov-Dec;17(6):1148–1156. [PubMed] [Google Scholar]
  20. Kesten S., Chaparro C., Scavuzzo M., Gutierrez C. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant. 1997 Sep;16(9):905–912. [PubMed] [Google Scholar]
  21. Lee H. A., Slapak M., Raman G. V., Mason J. C., Digard N., Wise M. Mizoribine as an alternative to azathioprine in triple therapy immunosuppressant regimens in cadaveric renal transplantation: two successive studies. Transplant Proc. 1995 Feb;27(1):1050–1051. [PubMed] [Google Scholar]
  22. Lipsky J. J. Mycophenolate mofetil. Lancet. 1996 Nov 16;348(9038):1357–1359. doi: 10.1016/S0140-6736(96)10310-X. [DOI] [PubMed] [Google Scholar]
  23. Nashan B., Moore R., Amlot P., Schmidt A. G., Abeywickrama K., Soulillou J. P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997 Oct 25;350(9086):1193–1198. doi: 10.1016/s0140-6736(97)09278-7. [DOI] [PubMed] [Google Scholar]
  24. Reichenspurner H., Soni V., Nitschke M., Berry G. J., Brazelton T. R., Shorthouse R., Huang X., Reitz B. A., Morris R. E. Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents. Transplantation. 1997 Aug 15;64(3):373–383. doi: 10.1097/00007890-199708150-00001. [DOI] [PubMed] [Google Scholar]
  25. Ross D. J., Lewis M. I., Kramer M., Vo A., Kass R. M. FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation. Chest. 1997 Nov 5;112(5):1175–1179. doi: 10.1378/chest.112.5.1175. [DOI] [PubMed] [Google Scholar]
  26. Ross D. J., Waters P. F., Levine M., Kramer M., Ruzevich S., Kass R. M. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant. 1998 Aug;17(8):768–774. [PubMed] [Google Scholar]
  27. Sarris G. E., Smith J. A., Shumway N. E., Stinson E. B., Oyer P. E., Robbins R. C., Billingham M. E., Theodore J., Moore K. A., Reitz B. A. Long-term results of combined heart-lung transplantation: the Stanford experience. J Heart Lung Transplant. 1994 Nov-Dec;13(6):940–949. [PubMed] [Google Scholar]
  28. Scott J. P., Higenbottam T. W., Sharples L., Clelland C. A., Smyth R. L., Stewart S., Wallwork J. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation. 1991 Apr;51(4):813–817. doi: 10.1097/00007890-199104000-00015. [DOI] [PubMed] [Google Scholar]
  29. Sehgal S. N., Molnar-Kimber K., Ocain T. D., Weichman B. M. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev. 1994 Jan;14(1):1–22. doi: 10.1002/med.2610140102. [DOI] [PubMed] [Google Scholar]
  30. Sibley R. K., Berry G. J., Tazelaar H. D., Kraemer M. R., Theodore J., Marshall S. E., Billingham M. E., Starnes V. A. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant. 1993 Mar-Apr;12(2):308–324. [PubMed] [Google Scholar]
  31. Sollinger H. W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995 Aug 15;60(3):225–232. doi: 10.1097/00007890-199508000-00003. [DOI] [PubMed] [Google Scholar]
  32. Speich R., Boehler A., Russi E. W., Weder W. A case report of a double-blind, randomized trial of inhaled steroids in a patient with lung transplant bronchiolitis obliterans. Respiration. 1997;64(5):375–380. doi: 10.1159/000196708. [DOI] [PubMed] [Google Scholar]
  33. Starzl T. E., Donner A., Eliasziw M., Stitt L., Meier P., Fung J. J., McMichael J. P., Todo S. Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. 1995 Nov 18;346(8986):1346–1350. doi: 10.1016/s0140-6736(95)92349-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Takao M., Higenbottam T. W., Audley T., Otulana B. A., Wallwork J. Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients. Transplant Proc. 1995 Feb;27(1):1284–1285. [PubMed] [Google Scholar]
  35. Theodore J., Lewiston N. Lung transplantation comes of age. N Engl J Med. 1990 Mar 15;322(11):772–774. doi: 10.1056/NEJM199003153221110. [DOI] [PubMed] [Google Scholar]
  36. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., Neylan J., Wilkinson A., Ekberg H., Gaston R. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998 Jan 15;338(3):161–165. doi: 10.1056/NEJM199801153380304. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES